A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Name: A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
License: Public Domain

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

ClinicalTrials.gov · Datasets · License: Public Domain

melanoma, ovarian cancer, sarcoma, non-small cell lung cancer, breast cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 429755
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.